Coherus Posts 94% Pegfilgrastim Margin Ahead Of Royalties To Amgen

 
• By Aidan Fry
Margin
Coherus believes it can maintain US pegfilgrastim gross margins above 90%, even while paying royalties to Amgen • Source: Shutterstock

More from Biosimilars

More from Products